W Jeffrey Petty

Summary

Affiliation: Wake Forest University School of Medicine
Country: USA

Publications

  1. doi request reprint High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer
    W Jeffrey Petty
    Department of Medicine, Wake Forest University Health Sciences, Winston Salem, NC, USA
    Lung Cancer 74:384-91. 2011
  2. pmc Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1α in vascular sarcomas
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
    BMC Cancer 12:404. 2012
  3. pmc Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    Clin Cancer Res 15:7398-404. 2009
  4. ncbi request reprint A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis
    W Jeffrey Petty
    Department of Pharmacology and Toxicology, Dartmouth College, Hanover, NH, USA
    J Natl Cancer Inst 97:1645-51. 2005
  5. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers
    W Jeffrey Petty
    Department of Pharmacology, Norris Cotton Cancer Center, Hanover, New Hampshire 03755, USA
    Clin Cancer Res 10:7547-54. 2004
  6. ncbi request reprint Bexarotene and erlotinib for aerodigestive tract cancer
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Norris Cotton Cancer Center, Lebanon, NH, USA
    J Clin Oncol 23:8757-64. 2005
  7. ncbi request reprint Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy
    Konstantin H Dragnev
    Norris Cotton Cancer Center, and Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
    Clin Cancer Res 10:2570-7. 2004
  8. ncbi request reprint Nonclassical retinoids and lung carcinogenesis
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Dartmouth Hitchcock Medical Center, Hanover, NH 03756, USA
    Clin Lung Cancer 6:237-44. 2005
  9. ncbi request reprint A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer
    Konstantin H Dragnev
    Sections of Hematology Oncology and Clinical Pharmacology, Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
    Clin Cancer Res 13:1794-800. 2007
  10. doi request reprint Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke
    Lynsay L Waller
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, NC, USA
    Lung Cancer 67:12-6. 2010

Collaborators

Detail Information

Publications17

  1. doi request reprint High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer
    W Jeffrey Petty
    Department of Medicine, Wake Forest University Health Sciences, Winston Salem, NC, USA
    Lung Cancer 74:384-91. 2011
    ..This study builds on prior work by examining the roles of cyclin D1, cyclin D3, and cyclin E in mediating erlotinib sensitivity or resistance...
  2. pmc Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1α in vascular sarcomas
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
    BMC Cancer 12:404. 2012
    ..The current study examines Ang-(1-7) induced changes in biomarkers according to cancer type and investigates mechanisms of action engaged in vitro...
  3. pmc Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    Clin Cancer Res 15:7398-404. 2009
    ..Secondary objectives were to assess toxicities, pharmacokinetics, clinical activity, and plasma biomarkers...
  4. ncbi request reprint A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis
    W Jeffrey Petty
    Department of Pharmacology and Toxicology, Dartmouth College, Hanover, NH, USA
    J Natl Cancer Inst 97:1645-51. 2005
    ..We previously reported that all-trans-retinoic acid (RA) treatment can prevent in vitro transformation of immortalized human bronchial epithelial (HBE) cells...
  5. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers
    W Jeffrey Petty
    Department of Pharmacology, Norris Cotton Cancer Center, Hanover, New Hampshire 03755, USA
    Clin Cancer Res 10:7547-54. 2004
    ..The current study sought to determine whether the EGFR TKI erlotinib repressed cyclin D1 protein expression in immortalized HBE cells, lung cancer cell lines, and clinical aerodigestive tract cancers...
  6. ncbi request reprint Bexarotene and erlotinib for aerodigestive tract cancer
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Norris Cotton Cancer Center, Lebanon, NH, USA
    J Clin Oncol 23:8757-64. 2005
    ..The rexinoid, bexarotene, represses cyclin D1 and EGFR expression in vitro. It was hypothesized that combining bexarotene with the EGFR inhibitor, erlotinib, would augment clinical activity...
  7. ncbi request reprint Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy
    Konstantin H Dragnev
    Norris Cotton Cancer Center, and Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
    Clin Cancer Res 10:2570-7. 2004
    ..G(1) arrest was triggered by cyclin D1 proteolysis via ubiquitin-dependent degradation. This study investigated which chemopreventive agents activated this degradation program and whether cyclin E was also degraded...
  8. ncbi request reprint Nonclassical retinoids and lung carcinogenesis
    Konstantin H Dragnev
    Hematology Oncology Section, Department of Medicine, Dartmouth Hitchcock Medical Center, Hanover, NH 03756, USA
    Clin Lung Cancer 6:237-44. 2005
    ..Results from randomized phase III clinical trials in NSCLC will ultimately determine the impact for rexinoid-based therapy or chemoprevention for lung cancer...
  9. ncbi request reprint A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer
    Konstantin H Dragnev
    Sections of Hematology Oncology and Clinical Pharmacology, Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
    Clin Cancer Res 13:1794-800. 2007
    ..The relationship between bexarotene levels and biomarker changes in tumor tissues has not been previously studied...
  10. doi request reprint Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke
    Lynsay L Waller
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, NC, USA
    Lung Cancer 67:12-6. 2010
    ..Individually, the selection and dosing of erlotinib for the treatment of lung cancer patients who continue to smoke is a clinical challenge...
  11. ncbi request reprint Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention
    Ian Pitha-Rowe
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
    Cancer Res 64:8109-15. 2004
    ..These findings also provide a mechanistic basis for the tumor suppressive effects of UBE1L through cyclin D1 repression...
  12. ncbi request reprint A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    J Thorac Oncol 2:197-202. 2007
    ..This phase II clinical trial was performed using a non-platinum-based chemotherapy doublet. The impact of previously identified polymorphisms on clinical outcomes was assessed...
  13. doi request reprint Effects of continued tobacco use during treatment of lung cancer
    Lynsay L Waller
    Department of Medicine, Section on Hematology and Oncology, Winston Salem, NC, USA
    Expert Rev Anticancer Ther 10:1569-75. 2010
    ..Future studies are needed to help define the best approach for encouraging smoking cessation, taking into account patient characteristics and the stress associated with the lung cancer diagnosis...
  14. pmc Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA
    Int J Oncol 43:2057-63. 2013
    ..8; 95% CI, 1.2-6.3; P=0.016). Intratumoral cyclin D3 expression did not impact clinical outcomes. Current smokers but not former smokers exhibit a higher erlotinib MTD. High cyclin D1 expression was associated with favorable TTP and OS...
  15. ncbi request reprint Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy
    Catherine B Swift
    Department of Medicine, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Endocr Metab Immune Disord Drug Targets 8:47-50. 2008
    ..Discerning isoform-specific functions will be critical for exploiting the full potential of retinoid-based therapy including rational approaches to combining retinoids with chromatin modifying drugs...
  16. ncbi request reprint The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, NC 27157 1030, USA
    Cancer 110:911-7. 2007
    ..This study was designed to investigate whether the mortality from heart disease, a manifestation of intercurrent disease after postoperative radiotherapy (PORT), has decreased over time for patients with nonsmall cell lung cancer (NSCLC)...
  17. ncbi request reprint Retinoid targets in cancer therapy and chemoprevention
    Konstantin H Dragnev
    Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Cancer Biol Ther 2:S150-6. 2003
    ..Different retinoid target genes likely trigger distinct effects. Identification of target genes is the next step towards a molecular understanding of mechanisms of retinoid response or resistance in cancer therapy and chemoprevention...